For research use only. Not for therapeutic Use.
Naftopidil, also known as Flivas and BM-15275, is an alpha-1-D adrenoceptor antagonist used to treat dysuria in men with benign prostatic hypertrophy.
| Catalog Number | A001132 |
| CAS Number | 57149-07-2 |
| Synonyms | KT-611 |
| Molecular Formula | C24H28N2O3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| Reference | </br>1:Medical expulsive therapy for ureter stone using naftopidil: A multicenter, randomized, double-blind, and placebo-controlled trial. Cho SY, Na W, Lee SW, Cho MC, Oh JJ, Lee S, Park J, Ahn S, Jeong CW.PLoS One. 2017 Apr 21;12(4):e0174962. doi: 10.1371/journal.pone.0174962. eCollection 2017. PMID: 28430785 Free PMC Article</br>2:Naftopidil Improves Symptoms in a Rat Model of Tranilast-Induced Interstitial Cystitis. Sugaya K, Nishijima S, Kadekawa K, Ashitomi K, Ueda T, Yamamoto H.Low Urin Tract Symptoms. 2017 May;9(2):107-110. doi: 10.1111/luts.12113. Epub 2015 Sep 26. PMID: 28394500 </br>3:Effect of Naftopidil on Bladder Microcirculation in a Rat Model of Bladder Outlet Obstruction. Majima T, Yamamoto T, Funahashi Y, Takai S, Matsukawa Y, Yoshida M, Gotoh M.Low Urin Tract Symptoms. 2017 May;9(2):111-116. doi: 10.1111/luts.12119. Epub 2015 Nov 6. PMID: 28394495 </br>4:Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips. Hattori T, Lluel P, Rouget C, Rekik M, Yoshiyama M.Int Neurourol J. 2017 Mar 24;21(1):20-28. doi: 10.5213/inj.1732758.379. PMID: 28361518 Free PMC Article</br>5:Efficacy and Safety of Naftopidil in the Medical Expulsion Therapy for Distal Ureteral Stone: A Systematic Review and Meta-Analysis. Li J, Tang Z, Gao L, Li J, Qin F, Yuan J.J Endourol. 2017 May;31(5):427-437. doi: 10.1089/end.2016.0486. Epub 2017 Mar 17. PMID: 28306333 </br>6:Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. Iwamoto Y, Ishii K, Kanda H, Kato M, Miki M, Kajiwara S, Arima K, Shiraishi T, Sugimura Y.J Cancer Res Clin Oncol. 2017 Jun;143(6):933-939. doi: 10.1007/s00432-017-2367-9. Epub 2017 Feb 27. PMID: 28243746 </br>7:Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo. Huang JJ, Cai Y, Huang MY, Zhu L, He F, Liu XW, Huang BY, Yi YZ, Yuan M.Eur J Pharmacol. 2016 Nov 15;791:473-481. doi: 10.1016/j.ejphar.2016.09.009. Epub 2016 Sep 9. PMID: 27615445 </br>8:Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver. Liu X, Zhu L, Huang B, Huang J, Cai Y, Zhu L, Wu B, Fu X, Zhang X, Rong Y, Xiao Q, Guo J, Li A, Guo Y, Yuan M.J Pharm Biomed Anal. 2017 Jan 5;132:165-172. doi: 10.1016/j.jpba.2016.09.038. Epub 2016 Sep 27. PMID: 27744175 </br>9:Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. Nakano T, Kuribayashi K, Mikami K.Expert Rev Anticancer Ther. 2016 Oct 8:1-3. [Epub ahead of print] No abstract available. PMID: 27718761 </br>10:Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury. Kadekawa K, Majima T, Kawamorita N, Okada H, Yoshizawa T, Mori K, Tyagi P, Sugaya K, Yoshimura N.Neurourol Urodyn. 2016 Oct 4. doi: 10.1002/nau.23158. [Epub ahead of print] PMID: 27701772 |
